SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board)
NNBP 0.00010000.0%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: donpat who wrote (84)8/23/2007 6:28:00 PM
From: donpat   of 106
 
BG-Medicine

HRP

The High-Risk Plaque Initiative ("HRP Initiative") is a joint research
and development effort to advance the understanding, recognition and
management of high-risk plaque for the benefit of all stakeholders in
the healthcare system. As the primary underlying cause of heart
attacks, high-risk, or vulnerable plaque is the number one cause of
death in the Western world. There are currently no methods of
screening, diagnosis or treatment for high-risk plaque.

The HRP Initiative will leverage recent advances in biology and
technology to design and optimize a care-cycle for high-risk plaque,
and promises to reduce morbidity, mortality and cost associated with
cardiovascular disease. This Initiative, which comprises specific
scientific studies and other activities, is being led by the world's
foremost scientists in the fields of cardiology, pathology, and
imaging, and is made possible through funding by leading
pharmaceutical and medical technology entities.
Goal of HRP Initiative

To provide a roadmap for development and registration of screening,
diagnostic and therapeutic interventions for high-risk plaque and
promote their proper use to the benefit of patients, providers and
payors.
Specific Goals

* Discover and validate screening blood biomarker
* Optimize non-invasive imaging methods for characterization of
high-risk patient, including:
o Develop and validate novel digital analyses methods of
images to characterize and classify patients
* Establish the relationship between imaging and blood biomarkers
and 3-year event rates
* Develop regulatory framework for HRP-related products
* Establish authoritative third-party source for HRP-related
information
* Explore development and validation of animal model for imaging
modalities

bg-medicine.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News